SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.

Autor: Ng DL; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Goldgof GM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Shy BR; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Levine AG; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Balcerek J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Bapat SP; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Prostko J; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA., Rodgers M; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA., Coller K; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA., Pearce S; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA., Franz S; Vitalant Research Institute, San Francisco, CA, USA., Du L; Vitalant Research Institute, San Francisco, CA, USA., Stone M; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Vitalant Research Institute, San Francisco, CA, USA., Pillai SK; Vitalant Research Institute, San Francisco, CA, USA., Sotomayor-Gonzalez A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Servellita V; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Martin CSS; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Granados A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Glasner DR; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Han LM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Truong K; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Akagi N; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Nguyen DN; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA., Neumann NM; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Qazi D; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Hsu E; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Gu W; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Santos YA; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Custer B; Vitalant Research Institute, San Francisco, CA, USA., Green V; Creative Testing Solutions, Tempe, AZ, USA., Williamson P; Creative Testing Solutions, Tempe, AZ, USA., Hills NK; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA., Lu CM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Laboratory Medicine Service, San Francisco VA Health Care System, San Francisco, CA, USA., Whitman JD; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Stramer SL; American Red Cross, Gaithersburg, MD, USA., Wang C; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Reyes K; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Hakim JMC; Department of Medicine at ZSFG, The Division of HIV, ID & Global Medicine, San Francisco, CA, USA., Sujishi K; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Alazzeh F; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Pham L; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Thornborrow E; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Oon CY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Miller S; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA., Kurtz T; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Simmons G; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Vitalant Research Institute, San Francisco, CA, USA., Hackett J Jr; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA., Busch MP; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Vitalant Research Institute, San Francisco, CA, USA., Chiu CY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA. charles.chiu@ucsf.edu.; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA. charles.chiu@ucsf.edu.; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA. charles.chiu@ucsf.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2020 Sep 17; Vol. 11 (1), pp. 4698. Date of Electronic Publication: 2020 Sep 17.
DOI: 10.1038/s41467-020-18468-8
Abstrakt: Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.
Databáze: MEDLINE